Open

Do GLP-1 receptor agonists improve liver & MASLD more than other treatments?

Also asked versus placebo.

Mechanistic model availableWhy does fat build up in the liver in type 2 diabetes?See where the mechanism fails, how this treatment's effect is predicted and validated against held-out trials, and the decisive experiments that remain. →

Where the evidence stands

Unlikely. So far, the results disagree.

NoUnsureYes
Belief
0.00 (range 0.00–0.55)
Trials for
0
Trials against
1
Inconclusive
0

Already under way

No registered trial that could settle this is recruiting or active.

The evidence so far

Registered trials
125
With posted results
34
Published papers
6

Of 7 decided analyses: 0 favor glp-1 receptor agonists, 5 find no difference, 2 favor the comparator.

Papers

Trials

See every trial in the evidence map →